Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
International Journal of COPD2013Vol. 8, pp. 501–501
Citations Over TimeTop 10% of 2013 papers
Abstract
The BEACON study demonstrated that once-daily QVA149 provides an efficacy and safety profile similar to the concurrent administration of its monocomponents indacaterol and glycopyrronium.
Related Papers
- → Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium(2010)89 cited
- → Indacaterol for the treatment of chronic obstructive pulmonary disease(2014)8 cited
- → Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD(2016)6 cited
- → A novel ultra long-acting bronchodilator——indacaterol(2010)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)